Project Grant 2032097

This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

Eradivir Inc. received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation to develop a therapeutic molecule for COVID-19. Under the grant, awarded February 15, 2021 for the period through January 31, 2022, Eradivir will conduct research at its facilities in West Lafayette, Indiana under the NSF's Engineering program (CFDA #47.041). The Engineering program seeks to improve quality of life and economic strength through fostering...

This $1 million cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a microbial discovery and biosynthesis platform for targeted protease inhibitors to treat COVID-19. Think Bioscience, Inc. will expand its demonstrated approach using microbial systems to guide the discovery and assembly of protease inhibitors. The company will generate new intellectual property covering the discovery platform and promising small molecules...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $867,563 to Rockefeller University to develop a novel class of nanobodies (NB) as a comprehensive defense against all beta-coronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. The key objectives are to expand the NB repertoire, identify synergistic NB combinations that are resistant to viral mutations, and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop broadly inhibitory antibody therapies against alphaviruses such as chikungunya virus (CHIKV) and Mayaro virus (MAYV). The $843,620 award to Albert Einstein College of Medicine, a private non-profit research institution, will fund efforts to: 1) engineer Fc mutations into existing broadly protective antibodies to...

The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...

Altigg Therapeutics, Inc. was awarded a $255,595 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) for the period of April 1, 2021 through March 31, 2022. Under this award, Altigg Therapeutics will develop a platform for the rapid discovery of human antibodies as therapeutics for infectious diseases such as COVID-19. The NSF Engineering program seeks to improve quality of life and economic strength through...

This $190,058 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to define the role of the protein ADAM9 in the immunopathogenesis of severe COVID-19 and its impact on acute lung injury. The research will be conducted at the University of Massachusetts Medical School (UMass Medical) and aims to build upon the grantee's preliminary findings that ADAM9 is...

The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...